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Deregulation of various components of the immune system has been reported in the inflamed gut of
Crohn’s disease (CD) patients. Innate lymphoid cells (ILCs) are novel innate effector lymphocytes which
can rapidly respond to danger signals, from invading pathogens or tissue damage, to maintain homeosta-
sis, especially along the mucosal surfaces. The purpose of this study is to compare composition of the
intestinal ILCs subsets of CD patients with differential inflammatory conditions of the terminal ileum,
which are marked by distinct histological appearances and mucosal profiles of cytokines. We observed
alterations in the frequency of LineageCRTH2CD45+NKp44CD117CD127+ILC subset in the inflamed
terminal ileum.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
CD is a debilitating, lifelong, relapsing, systemic inflammatory
disease that affects multiple parts of the gastrointestinal tract. Both
incidence and prevalence are increasing in Western countries. The
precise pathogenic mechanism of CD remains elusive. The interac-
tions of the environmental and genetic factors are thought to cause
an imbalance of the innate and adaptive immune responses in the
gut. Adaptive immunity has classically been considered to play a
major role in the pathogenesis of CD. However, a recent growing
body of evidence has shown that defective innate immunity also
plays important role in intestinal inflammation [1]. For the past
6 years, ILCs which have lymphoid morphology but are lacking
rearranged antigen specific surface receptors and surface lineage
markers have been the focus of intense research. These cells have
important effector and regulatory functions in innate immune
responses to infection, as well as in the orchestration of inflamma-
tion, homeostasis, and tissue remodeling throughout the body. This
is especially true at mucosal barriers [2,3]. Research of ILCs in
mouse models has greatly expanded our knowledge of this new
player in innate immunity [4]. However, the features of the ILCs
phenotype, function, maintenance, and how they are regulated in
the human are largely unknown. Detailed comparison of the char-acteristics of ILCs in diseased human samples with those in healthy
human samples will advance our evaluation of their contribution
to the progression of human diseases. It will also clarify their
potential therapeutic value for these diseases.2. Materials and methods
2.1. Reagents
Antibodies used for flow cytometric analyses are described in
Supplementary Materials and Methods.2.2. Human surgical intestinal samples processing and lamina propria
mononuclear cell (LPMC) isolation
The surgical samples of terminal ileum from CD patients were
obtained from UF Health Shands Hospital. Subsequent tissue sepa-
ration was achieved following an-IRB-approved protocol which
was previously documented [5]. Briefly, the process included
removing the outer fat tissue and muscle layer from fresh tissue
samples, cutting the remaining tissue into small strips, and vigor-
ously washing them 6–7 times with 25 ml stripping buffer (Mg2+
and Ca2+-free HBSS) containing 100 U/ml penicillin, 100 lg/ml
streptomycin, 25 lg/ml gentamycin, and 0.5 mM DTT, and then fil-
tering through a 400 lm mesh. The tissue remaining on top of the
mesh was further minced by a sterile surgical scalpel, and
Table 1
The clinical characteristics of patients with CD.
CD
patients
Gender Age Complication Medication
Patient
1
M 25 Ulceration in small bowel
and colon
Anti-TNFa
Humira
Patient
2
M 58 Ulceration in the colon Anti-TNFa
Remicade
Patient
3
M 28 Both small and large
intestines with fistula
Anti-TNFa
Remicade
Patient
4
M 37 Longitudinal fissures in the
colon
Anti-TNFa
Remicade and
Humira
Patient
5
M 25 No Anti-IL-12/23 p40
Ustekinumab
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pyruvate, supplemented with 75 U/ml Collagenase type XI, 20 lg/
ml Dispase neutral protease II, 500 U/ml DNase, 0.5 mM DTT and
1% FBS) at 37 C in the shaker for 30 min at a constant speed of
175 rpm. The remaining tissue was then mechanically dissociated
and filtered through a 70 lm cell strainer. All cells were slowly cry-
opreserved in cell freezing medium and transferred to liquid nitro-
gen for future use.
2.3. Flow cytometry
Each-cell suspension isolated from the terminal ileum was
incubated with LIVE/DEADTM Fixable Yellow dye on ice for 30 min,
stained with antibodies (anti-Human Lineage Cocktail 3, anti-C
D45/CD56/CD117/CD127/CRTH2/NKp44/CD117) at room tempera-
ture for 15 min, fixed with 100 ll of Fixation Medium for an addi-
tional 15 min, and washed. Data were acquired on a LSRII (BD
Biosciences, San Jose, CA) in the Cytometry Core at the University
of Florida, and analyzed using FlowJo software (Version 9.8.1, Tree
Star Inc., Ashland, OR). AbCTM Total Antibody Compensation beads
(Cat#A10497, Life technologies, Grand Island, NY) and ArCTM Amine
Reactive Compensation Bead (Cat#A10346, Life technologies,
Grand Island, NY) were used for compensation. Gating strategy
for the human intestinal ILC identification is shown in Supplemen-
tary Materials and Methods (Fig. S-1).
2.4. Quantitative RT-PCR
Total RNA from human intestinal tissue was isolated using QIA-
zol Lysis reagent (Qiagen, Valencia, CA), and then the SuperScript
VILO cDNA Synthesis Kit (Thermo Fisher Scientific) was used for
RT. PCR was performed using an ABI PRISM StepOnePlus Real time
PCR System (Thermo Fisher Scientific) in a 20 ll volume containing
the cDNA, 2  TaqMan Gene Expression Master Mix, Nuclease-
free water, and 1 Taqman Gene Expression Assay for Th-1 cytoki-
nes (Thermo Fisher Scientific). The mean of housekeeping gene
GAPDH was used as an internal control to normalize target gene
expression levels.
2.5. Histology
The fresh surgical samples of intestinal tissue were fixed in 10%
neutral-buffered formalin for 20 h, embedded in paraffin, sec-
tioned, and stained with hematoxylin and eosin.3. Results
3.1. Distinct histological appearance in the terminal ileum of CD
patients
We collected the terminal ileum samples from 5 CD patients
who underwent surgical treatment. The clinical characteristics of
patients with CD are listed in Table 1. According to the inflamma-
tory conditions of the terminal ileum, they are stratified into three
groups: CD patient with no ileum histological alterations or control
ileum (n = 1), mild terminal ileitis (n = 3), and moderate terminal
ileitis (n = 1). Compared to control ileum (Fig. 1A), Hematoxylin
and eosin staining of the mild ileitis group showed signs of active
chronic ileitis, including erosion and focal ulceration of the
mucosa, increased infiltration of inflammatory cells in the lamina
propria and mural fibrosis, while still maintaining the relatively
intact architecture (Fig. 1B and C). However, the moderate terminal
ileitis group demonstrated distorted mucosal architecture, thick-
ening of the wall, and higher-grade inflammatory cell infiltration
in the mucosa and lymphoid aggregates (Fig. 1D–F).3.2. Distinct mucosal inflammatory gene expression profiles in the
inflamed terminal ileum
Traditionally, CD has been associated with Th1 cell mediated
immune response [6]. To further evaluate the mucosal inflamma-
tion of our CD patient cohort, we quantified the mRNA expression
of typical Th1 cytokines IFN-c, TNF-a as well as Th-1 transcription
factor T-bet. IFN-c was upregulated more than 5-fold in the
inflamed terminal ileum of the mild ileitis group, and 16-fold in
the moderate ileitis group, as compared to the control ileum group
(Fig. 2A). Consistent with this, TBX21, which encoded transcription
factor T-bet, was upregulated more than 4-fold in the mild ileitis
group and 8-fold in the moderate ileitis group (Fig. 2C). However,
TNF-amRNA expression was similar between the mild and moder-
ate ileitis groups, an appropriately 7-fold upregulation, as com-
pared to the control ileum group (Fig. 2B). The abundance of Th1
cytokines contributed to the progressive tissue damage.3.3. Differential frequency of
LineageCRTH2CD45+NKp44CD117CD127+ILC subset in the
inflamed terminal ileum
As key orchestrators in immune defense at intestinal mucosal
surfaces, the ILCs (LineageCD45+CD127+) phenotype is very
important. We compared the composition of ILCs subsets in the
inflamed terminal ileum among the three groups, and observed
the alterations in the frequency of LineageCRTH2CD45+NKp44-
CD117CD127+ILC subset in the lamina propria. The percentage of
this subset among LineageCD45+CRTH2CD127+LPMC increased
from 19.5% in the control ileum group to roughly 47.5% in the mild
ileitis group, and 78.5% in the moderate ileitis group
(Fig. 3A and B). At the same time, we also noticed a gradually
decreased frequency of both NKp44+CD117+ and NKp44CD117+-
ILC subsets among LineageCD45+CRTH2CD127+LPMC in the ilei-
tis group (Fig. 3A and B). These results suggest that under
inflammatory conditions, the intestinal mucosal homeostasis is
disrupted, and the ILCs’ phenotype change dramatically. IL-12
and IL-23 have been reported to control the phenotype of CD127+-
ILCs in the intestinal lamina propria [7]. One patient in the mild
ileitis group received 5 months of treatment with anti-IL-12/23
p40 monoclonal antibody ustekinumab after the first surgery.
The histology showed signs of mucosal healing. IL-12A, IL-17A,
IL-22 and IL-23A mRNA expression decreased, even though IFN-
c, TNF-a and TBX21 expression levels were similar to those
obtained before treatment (Figs. 3C, D and S-2). Flow cytometric
analysis of LPMC from the inflamed terminal ileum revealed a
slight decrease of the frequency of LineageCRTH2CD45+NKp44-
CD117CD127+ILC subset, and a slight increase of the NKp44+-
CD117+ and NKp44CD117+ILC subsets (Fig. 3E and F).
D-F
A-C
Fig. 1. Representative HE staining demonstrates distinct histological appearance in the terminal ileum of CD patients. (A) Control ileum with no histological alteration. (B and
C) Mild ileitis group showed ulceration and increased infiltration of immune cells in the lamina propria. (D–F) Moderate ileitis group had higher level inflammatory cell
infiltration and mucosal architecture distortion. Scale bars: 500 lm (B, D and E), 100 lm (A, C and F).
Fig. 2. IFN-c, TNF-a and TBX21 mRNA expression profiles in the inflamed terminal ileum among control ileum (n = 1), mild ileitis (n = 3) and moderate ileitis (n = 1).
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In this study, we observed alterations in the frequency of
LineageCRTH2CD45+NKp44CD117CD127+ILC subset in the
inflamed terminal ileum of CD patients with different phases of
the disease process. The anti-IL-12/23 p40 monoclonal antibody,
ustekinumab showed its potential to regulate ILC phenotype plas-
ticity in the human intestine.
The plasticity of hematopoietic cells is illustrated by the switch
from one immune cell subset into another phenotypic and func-
tionally different subset in response to certain cytokines stimula-
tion, epigenetic modification, or microenvironment changes [8].
It is instrumental to drive appropriate specific immune responses
to protect the host. However, under certain circumstances, this
phenotype switch contributes to tissue damage in the pathogene-
sis of certain diseases [9,10]. The human intestinal ILCs plasticity in
the inflamed gut of CD patients is one of these conditions. Bernink
et al. proposed that under inflamed conditions the major ILC subset
NKp44+CD117+ILC3 at steady state could convert into IFN-c-
producing NKp44CD117CD127+ILC1 in response to Th1-related
cytokines. During this process, RORct, CD117, and NKp44 expres-
sions were lost, and T-bet expression was up-regulated [10]. The
increased IFN-c production was involved in the chronic intestinal
inflammation through the induction of intestinal epithelial cell
apoptosis and impairment of barrier function. This IFN-c-
producing NKp44CD117CD127+ILC1 subset is probably the samepopulation we observed which accumulated in the inflamed termi-
nal ileum of CD patients.
The decrease of ILC1 and recovery of ILC3 is crucial for the
maintenance of immune homeostasis in the gut. ILC3 can promote
proliferation of intestinal epithelial cells to contribute to wound
healing and tissue repair processes [11,12]. Also, ILC3 can stimu-
late the human epithelial cells to produce antimicrobial peptides
to initiate early host defense against invading bacterial pathogens
[13]. Additionally, human intestinal ILC3s can control auto-reactive
CD4+ T cells activation in the lamina propria through MHCII
expression [14–16].
The clinical trial of anti-IL-12/23 p40 monoclonal antibody,
ustekinumab demonstrated a significant benefit in CD patients
who had previously failed anti-TNF antibody treatment [17–19].
It is likely that ustekinumab’ regulation of intestinal ILC phenotype
plasticity contributes to this benefit.4.1. Conclusion
In conclusion, our study suggests that the frequency of
LineageCRTH2CD45+NKp44CD117CD127+ILC subset is differ-
entially altered in the inflamed terminal ileum of CD patients,
and the anti-IL-12/23 p40 monoclonal antibody ustekinumab
might be able to reverse this trend for better patient outcome.
Much remains to be investigated regarding the features of different
Fig. 3. Progressive accumulation of LineageCRTH2CD45+NKp44CD117CD127+ ILC subset in the inflamed terminal ileum among CD patients. (A) The accumulation of
LineageCRTH2CD45+NKp44CD117CD127+ILC subset in the inflamed terminal ileum among three groups after gating LineageCD45+CRTH2CD127+LPMC. (B) ILC subset
composition among three groups. (C) HE staining showed mucosal healing in the inflamed ileum of one patient in the mild ileitis group after 5 months anti-IL-12/23 p40
monoclonal antibody, ustekinumab treatment. Scale bars: 100 lm. (D) No difference in IFN-c, TNF-a and TBX21 mRNA expression after ustekinumab treatment. (E and F) A
slight decrease of NKp44-CD117-ILC subset in the ileum after 5 months ustekinumab treatment.
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Fig. 3 (continued)
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and eventually be able to manipulate ILC to combat disease.Conflict of interest
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